


INSERM:
THE WORLD'S SECOND
LEADING MEDICAL
RESEARCH INSTITUTE

(SCIMAGO)

ACCESS TO A MARKET OF
67
MILLION CONSUMERS
AND A GATEWAY TO EMEA MARKETS
(INSEE)



EURONEXT:
#1
EUROPEAN MARKET
FOR BIOTECHS
(FRANCE BIOTECHS)

BUSINESS FRANCE

77, boulevard Saint-Jacques
75680 Paris Cedex 14
Tel. : +33 1 40 73 30 00



KEY INFO IN
10
POINTS

**PHARMACEUTICALS
AND BIOTECH**

HIGH-TECH INDUSTRIES

APRIL 2019

1 THE WORLD'S 5TH LARGEST PHARMA MARKET

France is the fifth largest market in the world for human medicines, and the second largest in Europe. In 2017, revenues from pharmaceuticals amounted to €54.1 billion, nearly half of which were generated by exports (LEEM Pharmaceutical Industry Association, 2018). In 2018, French pharmaceutical exports increased by 1.8% to €27 billion. (French Customs Authorities)

2 SANOFI: AN INNOVATIVE LEADER

France is a key player in the pharmaceutical sector: Sanofi is the world's fourth largest pharmaceutical group in terms of revenues, which amounted to €45 billion in 2017. It employs more than 100,000 people in 100 countries and has 75 production sites around the world. In 2018, Sanofi invested €5.9 billion in R&D, and in 2017 it was the sixth largest company in Europe. (EPO)

3 INVESTING IN RESEARCH

The pharmaceutical industry has one of the highest business enterprise R&D budgets of any sector in France, accounting for 9.8% of pharmaceutical company revenues and 9% of all business enterprise research expenditure, which amounted to €2.9 billion in 2016 (LEEM Pharmaceutical Industry Association; MESRI, 2018). Inserm is currently ranked as the world's second leading medical research institute by Scimago.

4 €67 BILLION IN REVENUES

The biotech / medtech industry accounts for 330,000 direct and indirect jobs and had revenues of €67 billion in 2016. France has 720 biotech companies and 160 medtech companies, directly employing more than 50,000 people. By 2030, Healthtech could generate revenues of €40 billion. (DARES / LEEM Pharmaceutical Industry Association, as part of French Health Tech).

5 A FAVORABLE ECOSYSTEM

France has six competitiveness clusters dedicated to health: Lyon Biopôle, Medicen, Biovalley France, Atlanpole Biotherapies, Eurobiomed and Longevity Health Nutrition, which comprise 1,300 members, including 1,000 SMEs. R&D expenditure for medicines is eligible for the Research Tax Credit until the relevant product marketing authorization is granted.

6 A RESEARCH-LED SECTOR

Companies frequently use research partnerships. For biotechs, 46% are partnerships with academic research, one-third with major pharmaceutical companies and 16% with biotech companies. (France Biotech; Panorama France Health Tech, 2018)

7 EURONEXT PARIS: #1 EUROPEAN MARKET FOR BIOTECHS

With 91 health techs listed (including 68 from France), with a market capitalization of approximately €23 billion, Euronext is the leading European market for companies in the sector. In 2018, two French health tech companies were listed in Paris: Voluntis (e-health, €30.1 million raised) and Medincell (€30 million raised). (France Biotech; Panorama France Health Tech, 2018)

8 FRENCH HEALTHCARE

French Healthcare is an innovative initiative aimed at bringing together companies, researchers and healthcare professionals to jointly promote their activities internationally. The French Healthcare brand aims to bring different key players together to promote French expertise and health technology.

9 BUOYANT FOREIGN INVESTORS

In 2018, Business France recorded 45 job-creating foreign investment projects that created or maintained 1,394 jobs in the pharmaceutical and biotechnology sector in France. Germany's Merck CGaA has announced the expansion of its organic drug manufacturing process development center in Martillac, in Nouvelle Aquitaine, while South African company Aspen has expanded its sterile injectable product production facility in Normandy.

10 BIOTECHS RAISE FUNDS

Among the biotech startups that raised funds in 2018 were Dynacure, which develops new treatments for patients with serious genetic diseases (€47 million), Quantum Surgical, which intends to make its minimally invasive treatment for liver cancer more widely available (€43 million) and Enyo Pharma, which develops small therapeutic molecules to fight acute and chronic viral diseases such as hepatitis B (€40 million).